Our Locations
Helping millions of people across the globe—build families, stay healthy and fight disease
Locations
Headquartered in Switzerland, Ferring has locations worldwide, including 15 manufacturing facilities and 10 R&D centers, Our products are distributed in more than 100 countries around the world, reaching millions of patients in need. We currently have operating subsidiaries in more than 50 countries.
U.S. Locations
U.S. Headquarters
Parsippany, New Jersey
Our location in Parsippany, NJ, is the hub of our U.S. operations, including an on-site manufacturing facility. We’ve invested nearly $160 million in the creation of our U.S. headquarters. This state-of-the-art facility brings together clinical development, product supply and commercialization groups all under one roof. The complex sits on a 25-acre site and employs approximately 500 people in manufacturing, commercial operations, clinical development, management and administration. It’s where our people share ideas to ultimately develop, manufacture and market new therapies to help people build families, stay healthy and fight disease.
Corporate Affairs Office
Washington, D.C.
The Ferring Corporate Affairs Office is conveniently located near Capitol Hill and the White House. Here, Washington-based team members work to support Ferring business goals by engaging with legislators, advocacy groups, and stakeholders to shape policy in order to help people build families and live better lives.
Ferring Microbiome Inc.
Roseville, Minnesota
We’re not only investigating the microbiome to help people with certain diseases live better lives, we’re also using our learnings to understand its implications for bigger health challenges like cancer, chronic disease and other debilitating conditions.
Ferring’s late-stage clinical microbiome center, in Roseville, Minnesota, focuses on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. We have a diverse pipeline of investigational drug products built on the pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract.
Our microbiome team includes a passionate team of scientists, engineers and clinical researchers motivated by the opportunity to pioneer new therapies and technologies to meet today’s medical needs.
Global Locations
Learn more about our history